Structure of selective DYRK1A inhibitor GNF2133

GSK3β-sparing DYRK1A kinase inhibitor

orally efficacious in proliferation model, but non-specific proliferation observed

from cellular phenotypic screen and opt.

J. Med. Chem. Feb. 20, 2020

Novartis (GNF), San Diego, CA

GNF2133 (Novartis (GNF) oral in vivo GSK3-beta-sparing DYRK1A kinase inhibitor)

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.